Press Releases

July 2025

LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases

REDWOOD CITY, California and SHENZHEN, China – July 29, 2025 – LTZ Therapeutics (“LTZ”), an immunotherapy-focused biotechnology company, today announced a strategic research collaboration with Eli Lilly and Company (“Lilly”) to develop novel myeloid engager therapeutics against selected targets for the treatment of diseases with high unmet need.
July 2024

LTZ Therapeutics Announces Over $20 Million Series A Financing for Development of its Myeloid Engager-Based Immunotherapy Pipeline
May 2023

LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases
April 2022

LTZ Therapeutics Secures $17 Million Pre-Series A Financing for Immunotherapy Development to Treat Cancer & Other Complex Diseases

In The News

Follow Us
  • Stay ln Touch

    General Inquiries

    info@ltztherapeutics.com

    Business Development

    vivian.tian@ltztherapeutics.com
  • Locations

    Redwood City, USA

    1100 Island Dr., Suite 103, Redwood City, CA, 94065

    Shenzhen, China

    Room 209, Scientific Research Building, Tsinghua Hi-Tech Park, Nanshan District, Shenzhen, 518057

@ 2025 LTZ Therapeutics Inc., All Rights Reserved.

Privacy Policy | Term of Use | Contact Us

为了更好的呈现效果，移动端请竖屏浏览